BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2010
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Yrs cash pre-cut Cash date 1H10 oper loss
7/15/10 Adolor Corp. (NASDAQ:ADLR) 30% to ~80 $62.3 1.73 6/30/10 $18.0
Focusing on two programs: marketed drug Entereg alvimopan, a selective peripherally acting mu opioid receptor antagonist co-promoted in the U.S. for postoperative ileus (POI) with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); and its opioid bowel dysfunction (OBD) clinical program, which includes mu opioid receptor antagonists ADL7445 and ADL5945 in Phase I testing
8/3/10 Vectura Group plc (LSE:VEC) 31% to 190 $96.8 4.19 3/31/10 $23.1 (A)
Focusing on partnered programs and branded generics, and will seek licensing partners for its...

Read the full 745 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >